[go: up one dir, main page]

PE20001399A1 - Derivados 1-(2h-pirazol-3-ilo)-3-(naftalen-1-ilo)-urea - Google Patents

Derivados 1-(2h-pirazol-3-ilo)-3-(naftalen-1-ilo)-urea

Info

Publication number
PE20001399A1
PE20001399A1 PE2000000034A PE0000342000A PE20001399A1 PE 20001399 A1 PE20001399 A1 PE 20001399A1 PE 2000000034 A PE2000000034 A PE 2000000034A PE 0000342000 A PE0000342000 A PE 0000342000A PE 20001399 A1 PE20001399 A1 PE 20001399A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
ilo
naftalen
urea
Prior art date
Application number
PE2000000034A
Other languages
English (en)
Inventor
Pier F Cirillo
Thomas A Gilmore
Eugene R Hickey
John R Regan
Lin-Hua Zhang
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20001399A1 publication Critical patent/PE20001399A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLOS AROMATICOS DE FORMULA I, DONDE: Ar1 ES UN HETEROCICLO COMO PIRROL, PIRROLIDINA, PIRAZOL, IMIDAZOL, ENTRE OTROS; Ar2 ES FENILO, NAFTILO, QUINOLINA, ISOQUINOLINA, TETRAHIDRONAFTILO, ENTRE OTROS; L ES UNA CADENA CARBONADA C1-C10, UNO O MAS GRUPOS METILENO ESTAN OPCIONALMENTE REEMPLAZADOS CON O, N, S, OPCIONALMENTE SUSTITUIDOS CON 0-2 GRUPOS OXO, ALQUILO C1-C4; Q ES FENILO, NAFTILO, PIRIDINA, TETRAHIDROPIRANO, TETRAHIDROFURANO, ALCOXI C1-C6, ENTRE OROS; R1 ES ALQUILO C3-C10, CICLOALQUILO C3-C7, ALQUENILO C3-C10, CICLOALQUENILO C5-C7, CIANO, METOXICARBONILO; R2 ES ALQUILO C1-C6; R3 ES FENILO, NAFTILO, ARILO CONDENSADO, CICLOALQUILO, CICLOALQUENILO C5-C7, ENTRE OTROS; O R1 Y R2 FORMAN JUNTOS UN ANILLO CONDENSADO DE FENILO O PIRIDILO, R8 Y R13 SON H, ALQUILO C1-C4; R4, R5, R6, R7, R9, R10, R11, R12 SON MORFOLINA, PIPERIDINA, PIPERAZINA, ENTRE OTROS; m, r, t SON 0-2; X ES O, S. UN COMPUESTO PREFERIDO ES 1-[5-TERC-BUTIL-2-p-TOLIL-2H-PIRAZOL-3-IL]-3-[4-(2-MORFOLIN-4-IL-ETOXI)NAFTALEN-1-IL]UREA, ENTRE OTROS. UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I PUEDE SER UTIL PARA EL TRATAMIENTO DE UN ENFERMEDAD INFLAMATORIA COMO ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, ENFERMEDAD AUTOINMUNE
PE2000000034A 1999-01-19 2000-01-18 Derivados 1-(2h-pirazol-3-ilo)-3-(naftalen-1-ilo)-urea PE20001399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11640099P 1999-01-19 1999-01-19

Publications (1)

Publication Number Publication Date
PE20001399A1 true PE20001399A1 (es) 2000-12-20

Family

ID=22366966

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000034A PE20001399A1 (es) 1999-01-19 2000-01-18 Derivados 1-(2h-pirazol-3-ilo)-3-(naftalen-1-ilo)-urea

Country Status (33)

Country Link
US (6) US6319921B1 (es)
EP (1) EP1147104B1 (es)
JP (1) JP3793694B2 (es)
KR (1) KR100669839B1 (es)
CN (1) CN1333767A (es)
AR (1) AR034089A1 (es)
AT (1) ATE549328T1 (es)
AU (1) AU770581B2 (es)
BG (1) BG64971B1 (es)
BR (1) BR9916930A (es)
CA (1) CA2352524C (es)
CO (1) CO5150218A1 (es)
CZ (1) CZ20012635A3 (es)
EE (1) EE04527B1 (es)
HK (1) HK1041484A1 (es)
HR (1) HRP20010516A2 (es)
HU (1) HUP0201406A3 (es)
IL (2) IL143394A0 (es)
MX (1) MXPA01005628A (es)
MY (1) MY128063A (es)
NO (1) NO20013559L (es)
NZ (1) NZ513525A (es)
PE (1) PE20001399A1 (es)
PL (1) PL351764A1 (es)
RU (1) RU2220142C2 (es)
SA (1) SA00210018B1 (es)
SK (1) SK10192001A3 (es)
TR (1) TR200102072T2 (es)
TW (1) TW546297B (es)
UA (1) UA73492C2 (es)
WO (1) WO2000043384A1 (es)
YU (1) YU39101A (es)
ZA (1) ZA200104656B (es)

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
ATE266399T1 (de) 1998-08-20 2004-05-15 Smithkline Beecham Corp Neue substituierte triazolverbindungen
JP2002528506A (ja) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ME00275B (me) * 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
JP2002537397A (ja) 1999-02-22 2002-11-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての多環ヘテロ環式誘導体
WO2000055152A1 (en) * 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
CN1156452C (zh) 1999-03-12 2004-07-07 贝林格尔·英格海姆药物公司 作为消炎剂的化合物
WO2001004115A2 (en) 1999-07-09 2001-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
ATE281439T1 (de) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1294690A2 (en) * 2000-06-21 2003-03-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
MXPA02012909A (es) * 2000-07-24 2004-05-05 Boehringer Ingelheim Pharma Formulaciones mejoradas de dosis oral de 1-(5-ter-butil -2-p-tiolil2h -pirazol-3 -il)-3-(4-2 (2-morfolin-4-il -etoxi) -naftalen -1-il) -urea.
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1362037A1 (en) * 2001-02-15 2003-11-19 Boehringer Ingelheim Pharmaceuticals Inc. Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
JP2004531571A (ja) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
AU2002310156A1 (en) 2001-06-05 2002-12-16 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
DE60219793T2 (de) * 2001-07-11 2008-01-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US6808721B2 (en) * 2001-07-11 2004-10-26 Boehringer Ingelheim Pharmaceuticals, Inc. Methods for coating pharmaceutical core tablets
WO2003015828A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
CN1315781C (zh) 2001-08-31 2007-05-16 拜尔化学品股份公司 制备4－氨基－1－萘酚醚类化合物的方法
US7211575B2 (en) * 2001-09-13 2007-05-01 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
US6825184B2 (en) 2001-10-18 2004-11-30 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-Disubstituted benzo-fused urea compounds
EP1455791A1 (en) * 2001-12-11 2004-09-15 Boehringer Ingelheim Pharmaceuticals Inc. Method for administering birb 796 bs
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
DE60319066T2 (de) * 2002-02-25 2009-02-26 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
US20040044020A1 (en) * 2002-07-09 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
EP1549621A1 (en) * 2002-08-08 2005-07-06 Boehringer Ingelheim Pharmaceuticals Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
EP1545514A1 (en) 2002-08-14 2005-06-29 Boehringer Ingelheim Pharmaceuticals Inc. Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
EP1567507B1 (en) * 2002-11-27 2006-06-14 Boehringer Ingelheim Pharmaceuticals Inc. 1,2,3- triazole amide derivatives as cytokine inhibitors
US20040138216A1 (en) * 2002-12-23 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20080045531A1 (en) * 2002-12-31 2008-02-21 Flynn Daniel L Anti-inflammatory medicaments
NZ562413A (en) * 2003-02-21 2009-02-28 Resmed Ltd Headgear assembly for nasal pillows mask
ES2357288T3 (es) * 2003-02-28 2011-04-25 Bayer Healthcare Llc Derivados de 2-oxo-1,3,5-perhidrotriazapina útiles en el tratamiento de angiogénesis hiperproliferativa y trastornos inflamatorios.
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0320244D0 (en) * 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
CN101039957A (zh) 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
JPWO2004101529A1 (ja) * 2003-05-19 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
DK1636585T3 (da) 2003-05-20 2008-05-26 Bayer Pharmaceuticals Corp Diarylurinstoffer med kinasehæmmende aktivitet
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2004113352A1 (en) * 2003-06-19 2004-12-29 Amedis Pharmaceuticals Ltd. Silylated heterocyclylurea derivatives as cytokine-inhibitors
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
PT1663978E (pt) 2003-07-23 2008-02-15 Bayer Pharmaceuticals Corp Omega-carboxiaril difenil ureia substituída por flúor para o tratamento e a prevenção de doenças e estados patológicos
RU2006108864A (ru) * 2003-08-22 2007-09-27 Берингер Ингельхайм Фармасьютиклз, Инк. (Us) Способы лечения хронического обструктивного заболевания легких (хозл) и легочной гипертензии
BRPI0414313A (pt) 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
WO2005048953A2 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
WO2005063715A1 (en) * 2003-12-18 2005-07-14 Boehringer Ingelheim Pharmaceuticals, Inc. Polymorph of birb 796, a p38map kinase inhibitor
US20070191336A1 (en) * 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
PT1761520E (pt) * 2004-06-23 2008-09-15 Lilly Co Eli Inibidores de quinase
EP1609789A1 (en) * 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
DE602005010714D1 (de) 2004-08-12 2008-12-11 Pfizer Der p38-map-kinase
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US20080009519A1 (en) * 2004-11-17 2008-01-10 Lawrence Steinman Method of modulating t cell functioning
US20100041756A1 (en) * 2004-11-17 2010-02-18 Michael Lionel Selley method of modulating b cell functioning
ES2324173T3 (es) 2004-12-02 2009-07-31 Prosidion Limited Amidas del acido pirrolopiridin-2-carboxilico.
CA2589271A1 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7612200B2 (en) 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2005325676A1 (en) * 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1833819A1 (en) 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
CA2608258A1 (en) * 2005-05-12 2006-11-23 Boehringer Ingelheim International Gmbh Bis-amination of aryl halides
DE102005033103A1 (de) * 2005-07-15 2007-01-25 Bayer Healthcare Ag Heterocyclylamid-substituierte Thiazole, Pyrrole und Thiophene
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
WO2007044490A2 (en) * 2005-10-06 2007-04-19 Boehringer Ingelheim International Gmbh Process for making heteroaryl amine intermediate compounds
TW200800194A (en) * 2005-10-28 2008-01-01 Lilly Co Eli Kinase inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP2009518298A (ja) * 2005-12-01 2009-05-07 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療に有用な尿素化合物
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
EP1973408A2 (en) * 2006-01-04 2008-10-01 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
PL1981851T3 (pl) 2006-01-31 2012-07-31 Array Biopharma Inc Inhibitory kinazy i sposoby ich stosowania
WO2007091176A1 (en) * 2006-02-10 2007-08-16 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
KR20090018104A (ko) 2006-05-08 2009-02-19 어리어드 파마슈티칼스, 인코포레이티드 아세틸렌계 헤테로아릴 화합물
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
CN101636397B (zh) * 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 脲类化合物、其制备方法及其医药用途
EP2146716A4 (en) * 2007-04-20 2010-08-11 Deciphera Pharmaceuticals Llc KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE SYNDROME AND OTHER PROLIFERATIVE DISEASES
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
WO2009147682A1 (en) 2008-06-05 2009-12-10 Novotyr Therapeutics Ltd. Novel modulators of protein kinase signaling
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB0818033D0 (en) * 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
MX2011004535A (es) * 2008-10-29 2011-11-18 Deciphera Pharmaceuticals Llc Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
FR2937973B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
AU2009314631B2 (en) 2008-11-12 2014-07-31 Takeda Pharmaceutical Company Limited Pyrazinopyrazines and derivatives as kinase inhibitors
NZ593104A (en) * 2008-12-11 2012-11-30 Respivert Ltd P38 map kinase inhibitors
AR075974A1 (es) 2009-03-27 2011-05-11 Pathway Therapeutics Ltd Pirimidinil y 1,3,5-triazinilbencimidazolsulfonamidas y su uso en terapia del cancer
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
AU2010285740C1 (en) 2009-08-19 2016-03-17 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
WO2011040509A1 (ja) 2009-09-30 2011-04-07 東レ株式会社 ２，３－ジヒドロ－１ｈ－インデン－２－イルウレア誘導体及びその医薬用途
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
JP5787976B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
JP5973426B2 (ja) 2010-06-17 2016-08-23 レスピバート・リミテツド Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR102057058B1 (ko) 2011-10-03 2019-12-18 레스피버트 리미티드 P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
JP6495654B2 (ja) 2011-10-24 2019-04-03 アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー シクロヘキシルアミン類
BR112014013178A2 (pt) * 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
EP3553169B1 (en) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
EP2890701B1 (en) 2012-08-29 2017-03-29 Respivert Limited Kinase inhibitors
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
WO2014033447A2 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
ME02990B (me) 2012-11-13 2018-10-20 Array Biopharma Inc Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
SG11201503731SA (en) 2012-11-13 2015-06-29 Array Biopharma Inc Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
EP2981534B1 (en) 2013-04-02 2017-07-19 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
AU2014246866B2 (en) 2013-04-02 2018-05-10 Oxular Acquisitions Limited Kinase inhibitor
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
HK1219101A1 (zh) * 2013-06-06 2017-03-24 奇斯药制品公司 作为p38map激酶抑制剂的[1，2，4]三唑并[4，3-a]吡啶的衍生物
US9770454B2 (en) 2013-07-14 2017-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
JP6730701B2 (ja) 2013-11-14 2020-07-29 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
WO2015092423A1 (en) 2013-12-20 2015-06-25 Respivert Limited Urea derivatives useful as kinase inhibitors
CA2938924C (en) * 2014-02-14 2023-01-31 Respivert Limited Pyrazolyl-ureas as kinase inhibitors
MX2016014945A (es) 2014-05-15 2017-03-27 Array Biopharma Inc 1- ((3s,4r) -4- (3-fluorofenil) -1- (2-metoxietil) pirrolidin-3-il) -3- (4-metil-3- (2-metilpirimidin-5-il) -1-fenil-1h-pirazol-5-il) urea como inhibidor de trka cinasa.
WO2015173788A1 (en) 2014-05-16 2015-11-19 Westfaelische Wilhelms-Universitaet Muenster Novel anti-infective strategy against influenza virus and s. aureus coinfections
JP6659554B2 (ja) 2014-08-28 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 高純度キノリン誘導体およびその製造方法
LT3186232T (lt) 2014-08-29 2019-07-10 Torrent Pharmaceuticals Limited P38 map kinazė, slopinanti indanilo karbamido junginius
MA40775A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
AU2016213972B2 (en) 2015-02-05 2020-07-09 Tyrnovo Ltd. Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2017174995A1 (en) 2016-04-06 2017-10-12 Respivert Limited Kinase inhibitors
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
US11123349B2 (en) 2017-02-15 2021-09-21 The University Of Melbourne Method of treatment
EP3617195B1 (en) * 2017-04-27 2024-08-28 Mochida Pharmaceutical Co., Ltd. Novel tetrahydronaphthyl urea derivatives as inhibitors of tropomyosin receptor kinase a for the treatment of pain
KR20200013644A (ko) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종의 치료
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
CN111548313A (zh) * 2019-02-11 2020-08-18 绍兴从零医药科技有限公司 预防和治疗慢性疼痛药物的胍类化合物
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
ES2789898B2 (es) 2019-04-25 2021-10-14 Fund Profesor Novoa Santos Composicion para el tratamiento de los efectos secundarios de la radioterapia y/o quimioterapia
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
SMT202400484T1 (it) 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
SMT202300467T1 (it) 2019-12-30 2024-01-10 Deciphera Pharmaceuticals Llc Formulazioni di inibitori di chinasi amorfi e loro procedimenti d’uso
CN112961120B (zh) * 2021-02-06 2022-02-08 河南省锐达医药科技有限公司 一种萘基脲类化合物、其制备方法及应用
WO2023280911A1 (en) 2021-07-06 2023-01-12 Westfälische Wilhelms-Universität Münster P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm
CN114702439B (zh) * 2021-12-13 2023-11-10 河南省锐达医药科技有限公司 一类萘基脲-哌嗪类化合物及其制备方法和应用
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE293352C (es)
US4105766A (en) 1977-08-19 1978-08-08 Sterling Drug Inc. 4,5-Dihydro-5-oxopyrazolo[1,5-a]quinazoline-3-carboxylic acid derivatives
HU185294B (en) 1980-12-29 1984-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing substituted urea derivatives
JPS61228444A (ja) 1985-04-02 1986-10-11 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
EP0272866A1 (en) 1986-12-23 1988-06-29 Merck & Co. Inc. 1,4-Benzodiazepines with 5-membered heterocyclic rings
GB8908869D0 (en) 1989-04-19 1989-06-07 Shell Int Research A process for the preparation of aromatic ureas
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
DD293352A5 (de) 1990-04-06 1991-08-29 Adw,Zi Fuer Organische Chemie,De Verfahren zur herstellung von 2,2-disubstituierten 1-acyl- und/oder 9-acyl-2,3-dihydro-imidazo/1,2-a/benzimidazol-3-onen
RU2025473C1 (ru) * 1990-07-27 1994-12-30 Исихара Сангио Кайся Лтд. Производные бензоилмочевины или их фармацевтически приемлемые соли, обладающие противоопухолевой активностью
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
BR9306421A (pt) 1992-05-28 1998-09-15 Pfizer Novos derivados n-aril e n-heteroariluréia como inbidores da acilcoenzima a:colesterol aciltransferase (acat)
US5342942A (en) 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
GB9302275D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
WO1994022872A1 (fr) * 1993-03-30 1994-10-13 Yoshitomi Pharmaceutical Industries, Ltd. Inhibiteur d'adhesion cellulaire et compose a base de thienotriazolodiazepine
US5869043A (en) 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
US5783664A (en) 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
PT724588E (pt) 1993-09-17 2000-05-31 Smithkline Beecham Corp Proteina de ligacao a farmacos
JPH11503110A (ja) 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
WO1997016442A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
US6074862A (en) 1995-12-20 2000-06-13 Signal Pharmaceuticals Inc. Mitogen-activated protein kinase kinase MEK6 and variants thereof
EP0888335A4 (en) 1996-03-13 2002-01-02 Smithkline Beecham Corp NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
JP2000507545A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
EP0889888A4 (en) 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
US5948885A (en) 1996-05-20 1999-09-07 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
WO1997044467A1 (en) 1996-05-20 1997-11-27 Signal Pharmaceuticals, Inc. MITOGEN-ACTIVATED PROTEIN KINASE p38-2 AND METHODS OF USE THEREFOR
EP0906307B1 (en) 1996-06-10 2005-04-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
DE69731964T2 (de) 1996-10-09 2005-12-08 Medical Research Council Map-kinase: polypeptide, polynukleotide und ihre verwendung
WO1998024768A1 (en) 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Novel urea derivatives
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6376214B1 (en) 1997-02-18 2002-04-23 Smithkline Beecham Corporation DNA encoding a novel homolog of CSBP/p38 MAP kinase
DE69826695T2 (de) * 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE399007T1 (de) 1997-05-23 2008-07-15 Bayer Pharmaceuticals Corp Raf kinase hemmer
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US5851812A (en) 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
AU1367599A (en) * 1997-11-03 1999-05-24 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
CA2223075A1 (en) 1997-12-02 1999-06-02 Smithkline Beecham Corporation Drug binding protein
DE1041982T1 (de) * 1997-12-22 2001-06-07 Bayer Corp., Pittsburgh HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN
SK285371B6 (sk) * 1997-12-22 2006-12-07 Bayer Corporation Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom
NZ505844A (en) * 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
WO1999032110A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
PT1042305E (pt) 1997-12-22 2005-10-31 Bayer Pharmaceuticals Corp Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
WO1999046244A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
JP2002537397A (ja) 1999-02-22 2002-11-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての多環ヘテロ環式誘導体
WO2000055152A1 (en) * 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents

Also Published As

Publication number Publication date
IL143394A0 (en) 2002-04-21
CA2352524C (en) 2010-06-01
US6333325B1 (en) 2001-12-25
BR9916930A (pt) 2001-10-30
EE04527B1 (et) 2005-08-15
YU39101A (sh) 2005-06-10
US6319921B1 (en) 2001-11-20
IL143394A (en) 2011-08-31
EE200100376A (et) 2002-10-15
US20020058678A1 (en) 2002-05-16
AR034089A1 (es) 2004-02-04
RU2220142C2 (ru) 2003-12-27
MXPA01005628A (es) 2002-04-24
EP1147104A1 (en) 2001-10-24
US6329415B1 (en) 2001-12-11
US6506748B2 (en) 2003-01-14
SA00210018B1 (ar) 2006-08-12
BG64971B1 (bg) 2006-11-30
WO2000043384A1 (en) 2000-07-27
ZA200104656B (en) 2003-02-10
KR20010094748A (ko) 2001-11-01
UA73492C2 (en) 2005-08-15
CN1333767A (zh) 2002-01-30
SK10192001A3 (sk) 2001-12-03
US20020065285A1 (en) 2002-05-30
NO20013559D0 (no) 2001-07-18
BG105653A (bg) 2002-01-31
EP1147104B1 (en) 2012-03-14
HUP0201406A3 (en) 2003-11-28
ATE549328T1 (de) 2012-03-15
CZ20012635A3 (cs) 2001-11-14
CO5150218A1 (es) 2002-04-29
NZ513525A (en) 2004-05-28
CA2352524A1 (en) 2000-07-27
HK1041484A1 (zh) 2002-07-12
MY128063A (en) 2007-01-31
PL351764A1 (en) 2003-06-16
US6372773B1 (en) 2002-04-16
JP3793694B2 (ja) 2006-07-05
TR200102072T2 (tr) 2004-12-21
NO20013559L (no) 2001-07-18
HUP0201406A2 (en) 2002-08-28
HRP20010516A2 (en) 2002-08-31
AU770581B2 (en) 2004-02-26
AU1752200A (en) 2000-08-07
TW546297B (en) 2003-08-11
KR100669839B1 (ko) 2007-01-18
JP2003535023A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
PE20001399A1 (es) Derivados 1-(2h-pirazol-3-ilo)-3-(naftalen-1-ilo)-urea
ATE123771T1 (de) Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung.
PE20001484A1 (es) Derivados de naftalen-1-ilo urea y acido carbamico
DE60110066D1 (de) Piperidine zur verwendung als orexin rezeptor antagonisten
CA2035711A1 (en) 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
NO20081464L (no) 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer
NZ503794A (en) Benzimidazole and imidazopyridine derived heterocyclic compounds, pharmaceutical compositions and uses thereof
AR057107A2 (es) Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos
PE20030440A1 (es) Fenilsulfonamidas como antagonistas de ccr3
NO20072115L (no) Farmasoytiske forbindelser
EA200601852A1 (ru) Тетрагидрохинолиновые производные и способ их получения
AR019115A1 (es) Derivados de la 1-[(1-sustituido-4-piperidinil)metil]-4-piperidina, procesos para la preparacion de los mismos, composiciones farmaceuticas que loscontienen y los compuestos intermedios para prepararlos
PE20001303A1 (es) Derivados de la 4-aroilpiperidina como antagonistas del receptor ccr-3
RO82508B (ro) PROCEDEU PENTRU PREPARAREA UNOR DERIVATI DE 3-(1-PIPERIDINILACHIL)-4H-PIRIDO-(1,2-a)- PIRIMIDIN-4-ONA
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
NO20070457L (no) Pyrazolderivater
AR028817A1 (es) Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen
ES395714A1 (es) Procedimiento para la obtencion de derivados de piridoqui- nolina.
US3133061A (en) Piperidine carboxamides and derivatives thereof
AR045791A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
ES2038678T3 (es) Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos.
PE20050442A1 (es) Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de receptores muscarinicos de la acetilcolina
FR2801585B1 (fr) Nouveaux antagonistes des recepteurs de l'ii-8
PE51499A1 (es) Derivados de 5-aroilnaftaleno
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed